1	Effects of gender-affirming hormone therapy on gray matter
2	density, microstructure and monoamine oxidase A levels
3	in transgender subjects
4	
5 6 7 8	Handschuh PA*1, Reed MB*1, Murgaš M1, Vraka C2, Kaufmann U3, Nics L2, Klöbl M1, Ozenil M2, Konadu ME1, Patronas EM2, Spurny-Dworak B1, , Hahn A1, Hacker M2, Spies M1, Baldinger-Melich P1, Kranz GS1,4, Lanzenberger R1#. (*contributed equally)
9	¹ Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria
10	² Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine,
11	Medical University of Vienna, Austria.
12	³ Department of Obstetrics and Gynecology, Medical University of Vienna, Austria
13	⁴ Department of Rehabilitation Sciences, Hong Kong Polytechnic University, Hong Kong, China
14	
15	For submission to:
16	Medrxiv

17 Keywords: MRI, PET, gray matter, gender-affirming hormone therapy, sexual desire

Word count	279	Abstract						
	4516	Main section						
Figures: 3, Tables: 1, References: 91								

18

- 19 [#] Correspondence to:
- 20 Prof. Rupert Lanzenberger, MD, PD

- 21 Email: rupert.lanzenberger@meduniwien.ac.at
- 22 ORCID: https://orcid.org/0000-0003-4641-9539
- 23 Telephone: +43 (0)1 40400-35760

25 Highlights

26	•	Gender-affirming hormone therapy led to significant changes in gray matter density and

27 microstructure in various brain regions

- Gray matter changes found after gender-affirming hormone therapy were not reflected
- 29 by monoamone oxidase A density changes in the brain.
- Masculinizing gender-affirming hormone therapy resulted in increased sexual desire in
 transgender men.

33 Abstract

34 MAO-A catalyzes the oxidative degradation of monoamines and is thus implicated in sex-35 specific neuroplastic processes that influence gray matter (GM) density (GMD) and 36 microstructure (GMM). Given the exact monitoring of plasma hormone levels and sex steroid 37 intake, transgender individuals undergoing gender-affirming hormone therapy (GHT) represent 38 a valuable cohort to potentially investigate sex steroid-induced changes of GM and 39 concomitant MAO-A density. Here, we investigated the effects of long-term GHT over a median 40 time period of 4.5 months on GMD and GMM as well as MAO-A distribution volume. To this 41 end, 20 cisgender women, 11 cisgender men, 20 transgender women and 10 transgender men 42 underwent two MRI scans in a longitudinal design. PET scans using [¹¹C]harmine were 43 performed before each MRI session in a subset of 35 individuals. GM changes determined by 44 diffusion weighted imaging (DWI) metrics for GMM and voxel based morphometry (VBM) for 45 GMD were estimated using repeated measures ANOVA. Regions showing significant changes 46 of both GMM and GMD were used for the subsequent analysis of MAO-A density. These 47 involved the fusiform gyrus, rolandic operculum, inferior occipital cortex, middle and anterior 48 cingulum, bilateral insula, cerebellum and the lingual gyrus (post-hoc tests: p_{FWE+Bonferroni} < 49 0.025). In terms of MAO-A distribution volume, no significant effects were found. Additionally, 50 the sexual desire inventory (SDI) was applied to assess GHT-induced changes in sexual 51 desire, showing an increase of SDI scores among transmen. Changes in the GMD of the bilateral insula showed a moderate correlation to SDI scores (rho = -0.62, p_{Bonferroni} = 0.047). 52 53 The present results are indicative of a reliable influence of gender-affirming hormone therapy 54 on 1) GMD and GMM following an interregional pattern and 2) sexual desire specifically among 55 transmen.

57 Introduction

58 As pointed out in several reviews, meta- and mega-analyses that have been published over 59 the last decades, a multitude of studies on sex-specific differences in brain structure point 60 towards significant effects of sex steroids in terms of global, inter- and intra-regional brain 61 morphology (1-5). On average, female brains are smaller than male ones (6). Significant 62 differences between male and female brains were also found regarding gray (GM) and white 63 matter (WM) volumes (7, 8). Nevertheless, some studies failed to detect such differences in 64 GM volume on a global scale, despite adjustment for total brain size (9). Both region-of-interest 65 (ROI)-based approaches as well as voxel-wise analyses allow for the examination and 66 classification of highly specific cortical and subcortical regions, shedding light on a vast number 67 of potential regional and/or local sex differences (3-5). However, a closer look to the current 68 evidence reveals some inconsistent results, questioning the theory of a sexually dimorphic 69 brain and pointing towards a lack of features found reliably at one end of the continuum 70 between typically female and male brains (10).

71 Even though previous literature has reported conflicting results, it is known that sex hormones 72 are centrally involved in the biological mechanisms that drive sex-specific differences in brain 73 structure. Hence, ongoing research focusing on the interaction of cycling sex steroid levels 74 with components of the central nervous system is essential. Sex steroids are known to have both transcriptional as well as non-genomic effects (11-13), modifying the brain throughout the 75 76 lifespan (14-17). Thus, distributional differences in sex hormone receptors across the brain 77 (18-20) as well as sex-specific differences in axonal characteristics (21), neuroplasticity (22) 78 and neurogenesis (23) can be found. Additionally, sex steroids are known to directly interact 79 with various neurotransmitters (24-26) and their metabolism, e.g., by modulating the activity of 80 cerebral MAO-A activity. This has already been shown in a number of animal models (27-30) 81 and selected human studies (31), however in vivo imaging data acquired via positron emission 82 tomography (PET) remains scarce (32-34) and studies investigating the direct effects of 83 exogenously administered sex hormones on cerebral MAO-A are specifically

84 underrepresented (35). A further gap in the literature that needs to be addressed is given by 85 studies investigating the effect of MAOA gene polymorphisms that were shown to interact with 86 GM changes – despite knowledge on the influence of MAOA VNTR polymorphism on brain 87 structure volumes (36), cortical thickness (37) and gray matter (38), the association of MAO-A 88 protein expression as measured in human in vivo studies and GM is insufficiently investigated. 89 Taking into account the relevance of MAO-A density and subsequent neurotransmitter 90 metabolism on neuroplastic effects (39-41) and thus GM characteristics in the brain, the link 91 between MAO-A distribution and GM needs to be explored with multimodal imaging 92 techniques. Taking into account the additional effect of sex steroids on both MAO-A density 93 (32-34) as well as GM (7, 8), sex-specific interrelations of MAO-A density and GM might be of 94 interest.

95 Individuals with gender dysphoria (GD) receiving gender-affirming hormone therapy (GHT) 96 represent a unique cohort to investigate the direct effects of sex hormones on human brain structure. As described in the 5th edition of the Diagnostic and Statistical Manual of Mental 97 98 Disorders (DSM-V), GD is defined as an incongruence between the biological sex assigned at 99 birth and the experienced gender later in life (42). GHT basically involves the long-term 100 administration of an estrogen and a type of androgen blocker in transgender women (TW), 101 whereas the masculinization of transgender men (TM) can be supported by testosterone 102 treatment (43). As summarized by Kranz and colleagues, structural changes of the brain were 103 observed after GHT in a wide range of studies (44), with effects of testosterone treatment on 104 total brain volume (45, 46), GM and WM density (47-49) as well as cortical thickness, showing 105 controversial results in the latter (47, 50). In terms of estrogen and antiandrogen treatment, a 106 decrease in cortical thickness (47), total brain (45) as well as total GM and WM volume (46) 107 was shown. Changes in diffusivity as it was found after sex steroid treatment both in TM and 108 TW might be traced back to changes in the organizational properties of neural fibers (e.g., 109 axon diameter, fiber density, myelin staining) (44). On a molecular level, high-dose 110 testosterone treatment was shown to influence the distribution volume (V_T) of MAO-A in 111 transgender individuals (33). The structural and molecular effects of sex steroids on the brain

are also reflected by behavioralchanges, e.g., in terms of sexual behavior. In a cross-sectional multi-centered transgender study, Garz et al. could show that masculinizing GHT was associated with increased sexual desire in transmen (51). This is in line with the findings of Defreyne et al. (52), who reported a long-lasting increase of sexual desire as measured by the sexual desire inventory (SDI) in TM after GHT, whereas in TW, multiple SDI subscores decreased during the first three months of GHT.

118 In this longitudinal study, we aimed to investigate changes to brain morphology and 119 microstructure and further explore the corresponding effects on MAO-A binding in transgender 120 individuals after long-term GHT. To reveal alterations in GM density (GMD) and microstructure 121 (GMM) via MRI, voxel-based morphometry (VBM) and diffusion weighted imaging (DWI) were 122 applied. In a subset of participants, PET imaging using [¹¹C]harmine was conducted to uncover 123 the effects of sex steroid treatment on cerebral MAO-A density and to elucidate potential 124 interrelations between hormonally induced GM changes and alterations in MAO-A V_T. In 125 addition, we aimed to reveal the effect of GHT on sexual desire in both transmen and 126 transwomen.

127 Methods

This study was performed according to the Declaration of Helsinki, taking into account all
current revisions and good scientific practice guidelines of the Medical University of Vienna.
The study protocol was approved by the Ethics Committee of the Medical University of Vienna
(EC number 1104/2015) and registered at clinicaltrials.gov (NCT02715232).

132 Participants

Twenty cisgender women (CW), 11 cisgender men (CM), 20 TW and 10 TM men were enrolled in the study. Transgender subjects were recruited at the Unit for Gender Identity Disorder at the Department of Obstetrics & Gynecology, Division of Gynecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, Austria. Control subjects were recruited via designated message boards at the Medical University of Vienna and at other universities

138 in Vienna as well as via social media platforms. CW and CM were age and education level 139 matched to TW and TM, respectively. Importantly, for transgender individuals, inclusion criteria 140 comprised a diagnosis of gender dysphoria as defined in the Diagnostic and Statistical Manual 141 for Mental Disorders), version 5 (DSM-5: 302.85) or the International Classification of 142 Diseases, version 10 (ICD-10: F64.1). Moreover, the absence of severe psychiatric, neurologic 143 or internal comorbidities was ensured in case of study enrollment based on medical history, 144 physical examination, electrocardiogram, laboratory screening and structural clinical interview 145 (SCID) for DSM-V. All subjects gave written informed consent to take part in this study and 146 received financial compensation for their participation. Subjects were excluded in case of major 147 neurological or internal illnesses, pregnancy, current substance abuse (excluding smoking), 148 any kind of pathologic laboratory values, GHT or any other treatment with exogenous sex 149 hormones within 6 months prior to study enrollment, MRI contraindications, current or past 150 substance-related disorder or non-compliance (all subjects), any kind of current or prior 151 psychiatric diagnosis (CW and CM) or severe DSM-V comorbidities (TW and TM) as well as 152 current (TW and TM) or prior (CW and CM) treatment with psychotropic agents.

153 Study design

154 All subjects underwent two MRI scans separated by a median time period of 4.5 months 155 following a longitudinal study design. Each MRI session included structural (T1- and diffusion-156 weighted), task-based and resting-state MRI as well as MR spectroscopy. For the current 157 analyses, only structural MRI data was used. Thirty-five subjects (9 CW, 8 CM, 7 TW and 11 158 TM), underwent PET scan(s) that were performed before MRI acquisition using the radiotracer 159 [¹¹ C]harmine. After the baseline imaging sessions, transgender subjects received GHT. 160 Plasma hormone levels were assessed via blood draw right before or after each baseline and 161 follow-up imaging session. In addition, participants underwent the sexual desire inventory 162 2(SDI-2) to assess potential effects of GHT on participants' interest in sexual activity.

163 Medication

164 The following GHT protocol was applied at the Department of Obstetrics & Gynecology, 165 Division of Gynecologic Endocrinology and Reproductive Medicine, Medical University of 166 Vienna, Austria: TM were treated with either 1000 mg testosterone undecanoat every 8-16 167 weeks (Nebido 1000 mg / 4 ml i.m.), or up to 50 mg testosterone daily (Testogel 50 mg/day or 168 Testavan 23 mg/pump 1-2 pumps/day or testosterone crème as a magistral formula 12,5 169 mg/pump 3-4 pumps/day transdermally). If menstruation was still observed, transgender male 170 participants received either lynestrenol (Orgametril 5 mg 2-3 tablets/day p.o.) or desogestrel 171 (Monig Gynial or Cerazette 0.075 mg/day p.o.). TW received cyproterone acetate daily 172 (Androcur 50 mg/day) and either estradiol transdermally (Estramon 100 µg transdermal patch 173 2x/week or Estrogel gel 0.75-1.5 mg/day transdermally) or oral estradiol (Estrofem 4 mg/day 174 p.o.). In case of extensive hair loss, an alpha-5-reductase-inhibitor was prescribed (Finasterid 175 2.5 mg/48h Actavis/Arcana/Aurobindo p.o.). Furthermore, selected participants were treated 176 with GnRH-analogues like triptorelin (decapeptyl 0.1 mg/day subcutaneously).

177 Sex steroid monitoring

Levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), progesterone, estradiol,
testosterone, sex hormone binding globulin (SHBG) and dehydroepiandrosterone sulfate were
assessed via blood analysis at baseline and after a median time period of 4.5 months involving
GHT in transgender subjects and no treatment in cisgender controls.

182 Magnetic resonance imaging acquisition

All MRI data were recorded using a Siemens Prisma 3T scanner and a 64-channel head coil. A whole-brain T1-weighted scan was acquired with the following parameters: TE / TR = 2.91 / 2000 ms; inversion time = 900 ms; flip angle = 9°; matrix = 240 x 256, 176 slices; voxel size = 1.0 mm³; acquisition time = 7:59 min. Diffusion weighted images contained 64 diffusion encoded images, with a b-value of 800 s/mm² along with 7 non-diffusion (b=0) images (TE / TR=76 / 9400 ms, slice thickness = 1.6 mm, resolution=1.6 x 1.6 mm, matrix size=128 x 128 x 75, flip angle = 90°, acquisition time = 11:54 min). Subjects were instructed to stay awake

with eyes open and keep their head as still as possible during the entire scan to minimizemovement artifacts.

192 **Positron emission tomography**

193 Synthesis and quality control of [¹¹C]harmine, (7-[¹¹C]methoxy-1-methyl-9H-pyrido[3,4-194 blindole) were performed as previously published (53). All PET scans were performed using a 195 GE Advance full-ring scanner (General Electric Medical Systems, Milwaukee, WI, USA) at the 196 Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, 197 Medical University of Vienna (54-56). A 5 min transmission scan was done at the beginning of 198 the scan for tissue attenuation correction. Data acquisition started simultaneously with an 199 intravenous bolus injection of [¹¹C]harmine (4.6 MBg/kg body weight). Ninety minutes of PET 200 data were acquired in 3D mode and reconstructed using an iterative filtered backprojection 201 algorithm, which was separated into 51 time frames with a spatial resolution of 4.36 mm with 202 a FWHM of 1 cm next to the center of the field of view and reconstructed in 35 transaxial 203 sectional volumes (128 × 128 matrix). Automatic arterial blood sampling was performed during 204 the first 10 min at a rate of 4 ml/min (ALLOGG, Mariefred, Sweden) and manual samples were 205 taken at 5, 6, 7, 8, 10, 20, 40, 60, and 80 min after bolus start (57). A gamma counter previously 206 cross-calibrated to the PET scanner was used to measure radioactivity concentrations in both 207 whole blood and plasma. Furthermore, samples at 6, 7 and 8 min were used for individual 208 cross-calibration between manual and automated blood sampling. Fractions of radioactive 209 metabolites and the parent compound were determined with HPLC as described previously 210 (58).

211 MRI data processing

Voxel-based morphometric changes were calculated and processed in the CAT12 toolbox (http://www.neuro.uni-jena.de/cat/, version r1742) in MATLAB (version 9.8) using the longitudinal pipeline with default settings unless otherwise specified. Prior to preprocessing, raw data was visually inspected for potential artifacts. In short, the T1 images from both time points were co-registered, resampled and bias-corrected. Each scan was then skull stripped

and segmented into GM, white matter and cerebrospinal fluid, and resulting GMD was further
used. Finally, GMD maps were normalized into MNI space and spatially smoothed using an 8mm Gaussian kernel. Lastly, the CAT12 reports and data were visually controlled for
registrations and segmentation errors.

221 As an estimate for GMM changes, DWI data was processed within the FMRIB software library 222 (FSL. (https://bitbucket.org/reisert/unring), v. 6.0.05) (59)and unrina ANTs 223 (https://github.com/ANTsX/ANTs), MRtrix (https://www.mrtrix.org/) according to an optimized 224 pipeline (60). All data was brain-masked, corrected for noise, movement, gradient, Gibbs 225 ringing, bias field and eddy current distortions as well as for outliers in the form of signal 226 dropouts (60). The diffusion tensors were fitted using the "dtifit" command as well as the rotated 227 b-vectors and then smoothed using a 1 mm kernel (60). Mean diffusivity (MD) estimates were 228 calculated and co-registered with the participant- and measurement-specific segmented GMD 229 map. Thereafter, all images were normalized into MNI space and subsequently the GMD 230 segmentation was thresholded and used to mask out non-GM voxels. Finally, the DWI MD 231 estimates were smoothed using an 8 mm Gaussian kernel and masked again.

232 **PET data processing and MAO-A quantification**

233 MAO-A quantification was carried out using PMOD 3.509 (PMOD Technologies Ltd., Zurich, 234 Switzerland; www.pmod.com). Whole blood data was fitted with the sum of three exponentials 235 from the peak onward, plasma-to-whole blood ratio was fitted with a linear function and the 236 parent fraction was modeled with a Watabe function. The arterial input function (AIF) was 237 obtained by multiplying the fitted whole blood activity, plasma-to-whole blood ratio and the 238 fraction of intact radioligand in plasma. The Logan plot was used to quantify voxel-wise MAO-239 A total V_T with the thalamus as high uptake region. Regional V_T were extracted using the 240 activation map created from the overlap between GMD and DWI analyses.

241 Statistics

242 Structural changes determined by the MD DWI metric and GMD were estimated using 4 x 2 243 (group x time) repeated measures ANOVA (rmANOVA) implemented in SPM12. Interactions

244 between group (TM, TW, CW, CM) by time (before and after min. 4 months of hormone 245 therapy) were examined and further corrected for multiple testing using Gaussian random field 246 theory as implemented in SPM12 and the threshold for significance was set at $p \le 0.025$ family-247 wise error (FWE)-corrected according to (61) at the cluster-level following P \leq 0.001 248 uncorrected at the voxel-level. Further post-hoc comparisons and number of DWI metrics were 249 adjusted again using the Bonferroni method. To account for the individualized GHT treatment, 250 progesterone, testosterone and estradiol were added to both rmANOVA models as covariates. 251 Furthermore, the total intracranial volume was added as a covariate in the VBM model. For 252 both the GMD and DWI models each covariate was standardized, and group mean centered.

To provide a robust identification of hormonally induced gray matter alterations, the different structural changes reflected by both the GMD and DWI analyses were combined. The significant effects from both models were binarized and a conjunction map across both imaging modalities was calculated as an intersection. The remaining brain regions included in this conjunction map were used for the subsequent MAO-A V_T analysis.

258 Interaction effects in MAO-A V_T before and after GHT for both cis- and transgender individuals 259 were estimated using a linear mixed model in SPSS 25.0 (SPSS Inc., Chicago, Illinois; 260 www.spss.com). Here, the global model consisted of group, time and ROI (extracted from the 261 conjunction map) as factors and MAO-A V_T as the dependent variable. The model was reduced 262 in case of non-significance. Paired t-tests were used to estimate changes in SDI scores before 263 and after GHT for both transmales and transfemales ($p_{Bonferroni} < 0.025$). Finally, partial 264 correlations between changes in SDI scores to GMD and GMM while correcting for the main 265 influencing hormone were calculated to investigate a possible link between structural and 266 behavioral changes after GHT ($p_{Bonferroni} < 0.05$). The Bonferroni method was used to correct 267 for multiple comparisons in all tests.

268

270 **Results**

Demographics and hormone levels are listed in table 1. Fewer TW and matched CM were recruited when compared to TM and CW. Due to irreversible damage to the PET imaging equipment, 35 participants partook in the PET part of the study, where only 17 completed both scans, see table 1 for a detailed breakdown of subgroups. Out of the 35 participants that underwent the PET scans, only 52 scans were suitable for further analysis.

276 Structural and MAO-A changes after GHT

277 For both the VBM and DWI analyses, significant 2-way (time-by-group) interaction effects were 278 found. More widespread structural changes after a median of 4.5 months GHT using VBM 279 were discovered, when compared to MD, see figure 1a + b. Combining the results from VBM 280 and DWI analyses showed an overlap of changes in the fusiform gyrus, rolandic operculum, 281 inferior occipital cortex, middle and anterior cingulum and insula, cerebellum and the lingual 282 gyrus (figure 1c). Post-hoc tests revealed changes in GMD, see figure 2 and also for MD, figure 283 3, (p FWE + Bonferroni < 0.025). An increase in GMD was found in the fusiform gyrus, cerebellum 284 and lingual gyrus after GHT for transmen compared to both control groups. Transwomen 285 contrastingly showed a decrease in GMD after GHT in the rolandic operculum, insula, posterior 286 cingulum, cerebellum and lingual gyrus when compared to both cismales and cisfemales.

The opposite interaction effects were found in the MD of the fusiform and lingual gyrus for transmales compared to both cis control groups. An increase of MD in the insula was also found for transwomen after GHT when compared to both control groups.

290 When investigating regional changes in MAO-A V_T , no interaction and no main effects were 291 significant.

292 Behavioral changes after GHT

An increase in the overall SDI scale (sum score) "desire with (t = 5.84, $p_{Bonferroni} < 0.001$) and without interactions" (t = 3.4, $p_{Bonferroni} = 0.01$) was found for TM after GHT. Furthermore, a

moderate negative correlation between changes in the SDI sum score of desire with interaction and GMD in the bilateral insula after GHT for the TM group was found (rho = -0.62, p_{Bonferroni} = 0.047). While other regions and sum score of desire without interaction also showed moderate correlations, no others survived the correction for multiple comparisons. Moreover, no significant correlations between GMM and any SDI sum scores were found, p > 0.12.

301 Discussion

302 The present study aimed to investigate potential changes to GM and MAO-A density induced 303 by GHT over a median time period of 4.5 months in subjects with GD. To reveal robust changes 304 in both GD, morphometric differences in GMD and microstructural alterations as reflects by 305 GMM were combined and subsequently used for assessment of MAO-A V_T. Significant 306 changes in GMD and GMM after GHT that will be discussed in the following section were found 307 in nine distinct brain regions. Across these regions, no significant changes of MAO-A V_T were 308 found. In an additional analysis we probed the effect of GHT on sexual desire as measured by 309 the SDI and found an increase in the SDI sum scores "desire with" and "without interactions" 310 for TM after GHT.

311 Structural changes after GHT

Significant 2-way (time-by-group) interaction effects induced by GHT, as reflected by both the VBM and DWI analyses, were found in the fusiform gyrus, rolandic operculum, inferior occipital cortex, middle and anterior cingulum, bilateral insula, cerebellum as well as the lingual gyrus. As discussed in the following section, our findings are in line with prior studies reporting significant changes in GMD and GMM. Moreover, in comparison to cross-sectional data (62-66), our longitudinal design allows for more accurate interpretation.

318 Fusiform gyrus:

As various other regions presenting significant changes to GMD and GMM reported here, the fusiform gyrus is implicated in own-body perception in the context of self (49, 67) and is known to show different functional connectivity patterns in GD when compared to cisgender controls (49). These functionally different patterns might be reflected by structural differences as well. Here, we found a GHT-induced increase of GMD and decrease of MD (as a marker for GMM) in the fusiform gyrus of TM, potentially indicating anticatabolic effects of testosterone (44, 68).

325 Lingual gyrus, bilateral insula and posterior cingulum:

326 After and rogenization of TM, Zubiaurre-Elorza and colleagues found a significant increase of 327 cortical thickness in multiple brain regions, e.g., the left lingual gyrus (47). This is in line with our finding, however in the present study, GMD of the lingual gyrus increased and MD 328 329 decreased bilaterally across TM after high-dose testosterone treatment. Of note, the lingual 330 gyrus is centrally involved in processing visual information and thus visuospatial functioning. 331 As men, on average, perform better than women in visuospatial functioning, and testosterone 332 has been suggested to directly influence visuospatial functioning both in men (69) as well as 333 women (70), it could be hypothesized that advantages in this skill could partially be traced back 334 to an interrelation of higher GMD and and lower and the influence of high-dose testosterone 335 treatment. In addition, we found a significant decrease in GMD across the insula as well as the 336 posterior cingulum of TW when compared to CW and CM. The insula belongs to the salience 337 network (71), which plays a central role for interoceptive processes and own-body perception 338 (67). Differences in functional connectivity were further shown in language and affective 339 processing (72, 73) as well as in various neuropsychiatric conditions (74, 75). However, sex-340 based differences between cisgender men and women regarding the insula were not only 341 shown in functional MRI, but also in structural analyses (3) and investigations of the GABAergic 342 system in humans (76). Thus, changes to GMD might be seen as a marker for microstructural 343 remodeling induced by estrogen and anti-androgen therapy, as it is needed for multifactorial 344 adaptations that take place throughout GHT (49, 77). Our findings are in line with prior reports 345 on decreased GMD, higher MD reflecting microstructural changes, and widespread cortical 346 thinning in anti-androgen and estrogen treatment across TW (46, 47).

347

Changes to MAO-A distribution

348 In view of sexually dimorphic characteristics of multiple neuropsychiatric conditions, better 349 understanding of how sex steroids interact with neurotransmitters on a molecular level, e.g., 350 as reflected by MAO-A density, is of major interest. In the present study, none of the subgroups 351 showed significant changes to MAO-A V_T in any of the brain regions that were found to be 352 different in terms of GMD and GMM after GHT. In contrast, in a prior analysis of MAO-A density 353 after GHT performed by our group, we found statistically significant reductions of MAO-A V_T in

six of twelve previously defined regions of interest in TM after GHT for at least 4 months. These regions included the middle frontal cortex (-10%), anterior cingulate cortex (-9%), medial cingulate cortex (-10.5%), insula (-8%), amygdala (-9%) and hippocampus (-8.5%, all p<0.05)) (33). Of note, in the study by Kranz et al. regional MAOA V_T was estimated based on *a priori* defined regions-of-interest (ROIs) from a modified AAL atlas (33, 78), whereas here, MAO-A analysis was performed in regions that showed significant GMD and GMM changes after GHT.

361 GHT effects on sexual desire

362 The effect of GHT on sexual desire found here corroborates the findings of previous observations 363 reporting increased sexual desire in TM after androgen treatment (51, 52, 79-82). Even though 364 Defreyne et al. found that some sexual desire changes observed over the course of GHT might 365 diminish over time, elevated total, dyadic, and solitary SDI scores in TM remained stable on 366 the long-term (52). This is in line with our finding of elevated sexual desire in TM after a median 367 time period of 4.5 months of GHT. Despite the effects quantified 4.5 months after GHT 368 initiation, no further follow-up was performed in the present study. Therefore, a decrease of 369 sexual desire after a longer therapeutic period cannot be ruled out completely. However, a 370 follow-up period of 12 months has been performed by van Dijk and colleagues who reported 371 the most pronounced changes in sexual desire across TM within the first 3 months of treatment 372 which remained largely stable even after 12 months (81, 83). The increase in sexual desire 373 among TM might be traced back to testosterone treatment per se (84) and higher androgen 374 levels in general (85). However, many other factors could have influenced sexual drive, e.g., 375 more satisfactory sexual interactions and relationships due to transition or improvement in 376 general well-being after GHT (82).

Interestingly, partial correlation analyses between changes in SDI scores and GMD/GMM revealed a significant negative correlation between changes in the SDI sum score of desire with interaction and GMD in the bilateral insula of TM individuals. This finding suggests a possible connection between structural GM changes in the insula and changes in sexual desire

381 after masculinizing GHT. Among many other functions, the insula is essential for the integration 382 of external sensory stimuli via various neuronal pathways (86). Activation of the bilateral insula 383 during sexual arousal and desire has been shown in several fMRI studies (87-89), indicating a 384 link between insular activation and the processing of sexual stimuli. Although there have been 385 multiple fMRI studies in this area, this is, to the best of our knowledge, the first study to link 386 structural GM changes after long-term masculinizing GHT with changes in sexual desire. 387 Moreover, the significance of a negative (rather than positive) correlation between structural 388 GM changes and changes of sexual desire (found in subjects treated with testosterone) has 389 yet to be evaluated. Nevertheless, the finding points to an influence of the hormone on both 390 sexual desire and structural remodeling within cortical regions such as the insula.

Of note, also the neurotransmitter dopamine plays a key role in insular activation while processing sexual stimuli (90). Thus, the presence of mesolimbic dopaminergic projections reaching the insula and contributing to the processes taking place during sexual arousal and sexual desire should be considered in future neuroimaging studies in this field (91).

395 Limitations

Some limitations of the present study need to be addressed. First, subgroups were not sufficiently balanced due to recruitment difficulties, especially in case of subjects with gender dysphoria. Second, the subgroup that underwent PET imaging comprised only 17 individuals due to irreparable damages to the PET equipment. Therefore, it cannot be ruled out that potential GHT-induced changes in MAO-A V_T both on a global as could not be detected in the present analyses.

402 **Conclusion**

Long-term GHT seems to have a considerable impact on GMD and GMM in the brain of transgender individuals. Specific effects of either androgenizing or feminizing sex steroids must be taken into account in most regions, however, in selected structures both types of GHT affected GMD and GMM in the same way, pointing towards mechanisms that are induced by

GHT irrespective of whether feminizing or androgenizing steroids are used. The combined 407 408 approach in analyzing structural MRI data has the potential to shed light on changes of GM as 409 reflected by both morphometric as well as microstructural analyses after GHT in a longitudinal 410 design and in comparison to cisgender individuals. Nevertheless, larger sample sizes are 411 needed to detect reliable associations between GM and potential MAO-A density changes 412 induced by GHT. In terms of sexual desire, our findings are consistent with the literature and 413 supports evidence from previous observations of increased sexual desire in TM after 414 masculinizing GHT.

415 Acknowledgments

416 This research was funded in whole, or in part, by the Austrian Science Fund (FWF) [Grant 417 number KLI 504, PI: Rupert Lanzenberger]. M. Murgaš is funded by the Austrian Science Fund 418 (FWF) [Grant number DOC 33-B27, Supervisor R. Lanzenberger]. MB. Reed and M. Klöbl are 419 recipients of a DOC fellowship of the Austrian Academy of Sciences at the Department of 420 Psychiatry and Psychotherapy, Medical University of Vienna. This project was performed with 421 the support of the Medical Imaging Cluster of the Medical University of Vienna, and by the 422 grant "Interdisciplinary translational brain research cluster (ITHC) with highfield MR" from the 423 Federal Ministry of Science, Research and Economy (BMWFW), Austria. We thank the 424 graduated team members and the diploma students of the Neuroimaging Lab (NIL, headed by 425 R. Lanzenberger) as well as the clinical colleagues from the Department of Psychiatry and 426 Psychotherapy of the Medical University of Vienna for clinical and/or administrative support. In 427 particular, we would like to thank R. Seiger (MRI) and L. Rischka (PET) for technical and 428 methodological support and V. Ritter for administrative help. We would also like to thank N. 429 Berroterán-Infante, T. Balber, C. Philippe for assistance with radioligand synthesis, K. Rebhan 430 for radioligand metabolite processing, I. Leitinger, H. Ibeschitz, V. Weiss for assistance with 431 PET measurements, and V. Pichler, M. Mitterhauser, T. Traub-Weidinger and S. Kasper for 432 project supervision.

433

434 CRediT authorship contribution statement

Patricia A Handschuh; conceptualization, investigation, visualization, writing – original draft,
Murray B Reed; conceptualization, methodology, software, formal analysis, data curation,
visualization, writing – original draft, Matej Murgaš; software, data curation, review & editing,
Crysoula Vraka; review & editing, Ulrike Kaufmann; review & editing, investigation, Lukas
Nics; review & editing, Marius Ozenil; review & editing, Dr. Melisande E. Konadu;
investigation, review & editing, Manfred Klöbl; investigation, data curation, writing – review &

editing, Eva-Maria Patronas; review & editing, Benjamin Spurny-Dworak; review & editing,
Andreas Hahn; software, supervision, writing – review & editing, Marcus Hacker; review &
editing, Marie Spies; conceptualization, investigation, writing – review & editing, Pia
Baldinger-Melich; review & editing, investigation, Georg S. Kranz; conceptualization, writing
review & editing, Rupert Lanzenberger; project administration, funding acquisition,
supervision

447 **Conflict of Interest**

With relevance to this work there is no conflict of interest to declare. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. G.S. Kranz declares that he received conference speaker honorarium from Roche, AOP Orphan and Pfizer. P. Handschuh received authorship honoraria from MedMedia Verlag and a travel grant from Angelini Pharma. The other authors report no conflict of interest.

455 Data availability statement

456 Due to data protection laws processed data is available from the authors upon reasonable 457 request. Please contact rupert.lanzenberger@meduniwien.ac.at with any questions or 458 requests.

perpetuity. All rights reserved. No reuse allowed without permission.

460 References

461 1. Cosgrove KP, Mazure CM, Staley JK. Evolving Knowledge of Sex Differences in Brain 462 Structure, Function, and Chemistry, Biological Psychiatry, 2007:62(8):847-55.

463 Luders E, Kurth F. Structural differences between male and female brains. Handbook 2. 464 of clinical neurology. 2020;175:3-11.

465 Ruigrok AN, Salimi-Khorshidi G, Lai MC, Baron-Cohen S, Lombardo MV, Tait RJ, et al. 3. 466 A meta-analysis of sex differences in human brain structure. Neuroscience and biobehavioral 467 reviews. 2014;39(100):34-50.

468 Kong X-Z, Mathias SR, Guadalupe T, Glahn DC, Franke B, Crivello F, et al. Mapping 4. 469 cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium. 470 Proceedings of the National Academy of Sciences. 2018;115(22):E5154-E63.

471 Guadalupe T, Mathias SR, vanErp TGM, Whelan CD, Zwiers MP, Abe Y, et al. Human 5. 472 subcortical brain asymmetries in 15,847 people worldwide reveal effects of age and sex. Brain 473 imaging and behavior. 2017;11(5):1497-514.

Allen JS, Damasio H, Grabowski TJ. Normal neuroanatomical variation in the human 474 6. 475 brain: an MRI-volumetric study. American journal of physical anthropology. 2002;118(4):341-476 58.

477 7. Gur RC, Turetsky BI, Matsui M, Yan M, Bilker W, Hughett P, et al. Sex differences in 478 brain gray and white matter in healthy young adults: correlations with cognitive performance. 479 The Journal of neuroscience : the official journal of the Society for Neuroscience. 480 1999;19(10):4065-72.

481 Luders E, Gaser C, Narr KL, Toga AW. Why Sex Matters: Brain Size Independent 8. 482 Differences in Gray Matter Distributions between Men and Women. The Journal of 483 Neuroscience. 2009;29(45):14265.

484 Nopoulos P, Flaum M, O'Leary D, Andreasen NC. Sexual dimorphism in the human 9. 485 brain: evaluation of tissue volume, tissue composition and surface anatomy using magnetic 486 resonance imaging. Psychiatry research. 2000;98(1):1-13.

Joel D, Berman Z, Tavor I, Wexler N, Gaber O, Stein Y, et al. Sex beyond the genitalia: 487 10. 488 human brain mosaic. Proceedings of the National Academy of Sciences. The 489 2015;112(50):15468-73.

490 11. Singh M, Su C, Ng S. Non-genomic mechanisms of progesterone action in the brain. 491 Frontiers in neuroscience. 2013;7:159.

- 492 Kawata M, Nishi M, Matsuda K, Sakamoto H, Kaku N, Masugi-Tokita M, et al. Steroid 12. 493 receptor signalling in the brain--lessons learned from molecular imaging. Journal of 494 neuroendocrinology. 2008;20(6):673-6.
- 495 Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. European 13. 496 journal of endocrinology. 2003;148(3):281-92.

497 Koolschijn PCM, Peper JS, Crone EA. The influence of sex steroids on structural brain 14. 498 maturation in adolescence. PloS one. 2014;9(1):e83929.

499 Pike CJ. Sex and the development of Alzheimer's disease. Journal of neuroscience 15. 500 research. 2017;95(1-2):671-80.

Knickmeyer RC, Wang J, Zhu H, Geng X, Woolson S, Hamer RM, et al. Impact of sex 501 16. 502 and gonadal steroids on neonatal brain structure. Cerebral cortex (New York, NY: 1991). 503 2014;24(10):2721-31.

504 Mills KL, Lalonde F, Clasen LS, Giedd JN, Blakemore SJ. Developmental changes in 17. 505 the structure of the social brain in late childhood and adolescence. Social cognitive and 506 affective neuroscience. 2014;9(1):123-31.

507 Österlund MK, Gustafsson J-Ak, Keller E, Hurd YL. Estrogen receptor β (ER β) 18. 508 messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERa mRNA. The Journal of Clinical Endocrinology & Metabolism. 509 510 2000;85(10):3840-6.

511 19. Brinton RD, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE, et al. Progesterone 512 receptors: Form and function in brain. Frontiers in Neuroendocrinology. 2008;29(2):313-39.

513 20. Fernández-Guasti A, Kruijver FP, Fodor M, Swaab DF. Sex differences in the 514 distribution of androgen receptors in the human hypothalamus. Journal of Comparative 515 Neurology. 2000;425(3):422-35.

516 21. Ibanez C, Shields SA, El-Etr M, Leonelli E, Magnaghi V, Li WW, et al. Steroids and the 517 reversal of age-associated changes in myelination and remyelination. Progress in 518 Neurobiology. 2003;71(1):49-56.

519 22. Baroncini M, Jissendi P, Catteau-Jonard S, Dewailly D, Pruvo J-P, Francke J-P, et al. 520 Sex steroid hormones-related structural plasticity in the human hypothalamus. NeuroImage. 521 2010;50(2):428-33.

522 23. Heberden C. Sex steroids and neurogenesis. Biochemical pharmacology. 523 2017;141:56-62.

524 24. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. Reviews in the 525 Neurosciences. 1994;5(1):27-42.

526 25. Dubol M, Epperson CN, Sacher J, Pletzer B, Derntl B, Lanzenberger R, et al. 527 Neuroimaging the menstrual cycle: A multimodal systematic review. Frontiers in 528 Neuroendocrinology. 2021;60:100878.

529 26. Zheng P. Neuroactive steroid regulation of neurotransmitter release in the CNS: action, 530 mechanism and possible significance. Progress in neurobiology. 2009;89(2):134-52.

531 27. Luine VN, McEwen BS. Effect of oestradiol on turnover of type A monoamine oxidase 532 in brain. Journal of neurochemistry. 1977;28(6):1221-7.

533 28. Holschneider DP, Kumazawa T, Chen K, Shih JC. Tissue-specific effects of estrogen 534 on monoamine oxidase A and B in the rat. Life Sci. 1998;63(3):155-60.

535 29. Smith LJ, Henderson JA, Abell CW, Bethea CL. Effects of ovarian steroids and 536 raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of 537 macaques. Neuropsychopharmacology. 2004;29(11):2035-45.

538 30. Bethea CL, Phu K, Kim A, Reddy AP. Androgen metabolites impact CSF amines and 539 axonal serotonin via MAO-A and -B in male macaques. Neuroscience. 2015;301:576-89.

540 31. Klaiber EL, Broverman DM, Vogel W, Peterson LG, Snyder MB. Individual differences 541 in changes in mood and platelet monoamine oxidase (MAO) activity during hormonal 542 replacement therapy in menopausal women. Psychoneuroendocrinology. 1996;21(7):575-92.

543 32. Rekkas PV, Wilson AA, Lee VW, Yogalingam P, Sacher J, Rusjan P, et al. Greater 544 monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled 545 harmine positron emission tomography. JAMA Psychiatry. 2014;71(8):873-9.

546 33. Kranz GS, Spies M, Vraka C, Kaufmann U, Klebermass E-M, Handschuh PA, et al.
547 High-dose testosterone treatment reduces monoamine oxidase A levels in the human brain: A
548 preliminary report. Psychoneuroendocrinology. 2021;133:105381.

549 34. Sacher J, Wilson AA, Houle S, Rusjan P, Hassan S, Bloomfield PM, et al. Elevated 550 brain monoamine oxidase A binding in the early postpartum period. Archives of general 551 psychiatry. 2010;67(5):468-74.

552 35. Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, et al. High-553 Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender 554 People. Biol Psychiatry. 2015;78(8):525-33.

555 36. Wassink TH, Hazlett HC, Davis LK, Reiss AL, Piven J. Testing for association of the 556 monoamine oxidase A promoter polymorphism with brain structure volumes in both autism and 557 the fragile X syndrome. Journal of neurodevelopmental disorders. 2014;6(1):6.

558 37. Cerasa A, Cherubini A, Quattrone A, Gioia MC, Magariello A, Muglia M, et al.
559 Morphological correlates of MAO A VNTR polymorphism: new evidence from cortical thickness
560 measurement. Behavioural brain research. 2010;211(1):118-24.

38. Meyer-Lindenberg A, Buckholtz JW, Kolachana B, A RH, Pezawas L, Blasi G, et al.
Neural mechanisms of genetic risk for impulsivity and violence in humans. Proceedings of the
National Academy of Sciences of the United States of America. 2006;103(16):6269-74.

39. Naoi M, Maruyama W, Shamoto-Nagai M. Type A monoamine oxidase and serotonin
are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired
neurogenesis. Journal of neural transmission (Vienna, Austria : 1996). 2018;125(1):53-66.

567 40. Godar SC, Bortolato M, Richards SE, Li FG, Chen K, Wellman CL, et al. Monoamine 568 oxidase A is required for rapid dendritic remodeling in response to stress. International Journal 569 of Neuropsychopharmacology. 2015;18(9):pyv035.

570 41. Soliman A, Udemgba C, Fan I, Xu X, Miler L, Rusjan P, et al. Convergent effects of 571 acute stress and glucocorticoid exposure upon MAO-A in humans. Journal of Neuroscience. 572 2012;32(48):17120-7.

573 42. Association AP, DSM-IV. APATFo. Diagnostic and Statistical Manual of Mental 574 Disorders, Fourth Edition: DSM-IV-TR®: American Psychiatric Association; 2000.

43. Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et
al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine
Society* Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism.
2017;102(11):3869-903.

- 44. Kranz GS, Zhang BBB, Handschuh P, Ritter V, Lanzenberger R. Gender-affirming
 hormone treatment A unique approach to study the effects of sex hormones on brain structure
 and function. Cortex; a journal devoted to the study of the nervous system and behavior.
 2020;129:68-79.
- 583 45. Pol HEH, Cohen-Kettenis PT, Van Haren NE, Peper JS, Brans RG, Cahn W, et al. 584 Changing your sex changes your brain: influences of testosterone and estrogen on adult 585 human brain structure. European Journal of Endocrinology. 2006;155(suppl_1):S107-S14.
- 586 46. Kilpatrick LA, Holmberg M, Manzouri A, Savic I. Cross sex hormone treatment is linked 587 with a reversal of cerebral patterns associated with gender dysphoria to the baseline of 588 cisgender controls. European Journal of Neuroscience. 2019;50(8):3269-81.
- 589 47. Zubiaurre-Elorza L, Junque C, Gómez-Gil E, Guillamon A. Effects of Cross-Sex 590 Hormone Treatment on Cortical Thickness in Transsexual Individuals. The Journal of Sexual 591 Medicine. 2014;11(5):1248-61.
- 48. Kranz GS, Hahn A, Kaufmann U, Tik M, Ganger S, Seiger R, et al. Effects of testosterone treatment on hypothalamic neuroplasticity in female-to-male transgender individuals. Brain Structure and Function. 2018;223(1):321-8.
- 595 49. Burke SM, Manzouri AH, Dhejne C, Bergström K, Arver S, Feusner JD, et al. 596 Testosterone Effects on the Brain in Transgender Men. Cerebral Cortex. 2017;28(5):1582-96. 597 50. Hahn A, Kranz GS, Sladky R, Kaufmann U, Ganger S, Hummer A, et al. Testosterone 598 affects language areas of the adult human brain. Human brain mapping. 2016;37(5):1738-48. 599 Garz M, Schröder J, Nieder T, Becker I, Biedermann S, Hildebrandt T, et al. Body 51. 600 Image and Sexual Desire in the Context of Gender Affirming Therapy: Results of a Crosssectional Multi-centered Transgender Study. Journal of Sex & Marital Therapy.
- 601 sectional Multi-centered 602 2021;47(5):435-45.
- 52. Defreyne J, Elaut E, Kreukels B, Fisher AD, Castellini G, Staphorsius A, et al. Sexual desire changes in transgender individuals upon initiation of hormone treatment: Results from the longitudinal European Network for the Investigation of Gender Incongruence. The Journal of Sexual Medicine. 2020;17(4):812-25.
- 53. Philippe C, Zeilinger M, Mitterhauser M, Dumanic M, Lanzenberger R, Hacker M, et al.
 Parameter evaluation and fully-automated radiosynthesis of [11C]harmine for imaging of MAOA for clinical trials. Applied Radiation and Isotopes. 2015;97:182-7.
- 54. Baldinger-Melich P, Gryglewski G, Philippe C, James GM, Vraka C, Silberbauer L, et al. The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain stimulation. 2019;12(3):714-23.
- 55. Spies M, James GM, Vraka C, Philippe C, Hienert M, Gryglewski G, et al. Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. 2018;8(1):198.
- 56. James GM, Baldinger-Melich P, Philippe C, Kranz GS, Vanicek T, Hahn A, et al. Effects
 of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter
 Availability in Major Depression. Frontiers in human neuroscience. 2017;11:48.
- 620 57. Ginovart N, Meyer JH, Boovariwala A, Hussey D, Rabiner EA, Houle S, et al. Positron 621 emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the

human brain. Journal of cerebral blood flow and metabolism : official journal of the International
 Society of Cerebral Blood Flow and Metabolism. 2006;26(3):330-44.

624 58. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC 625 for the analysis of plasma in PET imaging studies. Nuclear medicine and biology. 626 2000;27(6):627-30.

59. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg
H, et al. Advances in functional and structural MR image analysis and implementation as FSL.
NeuroImage. 2004;23:S208-S19.

630 60. Maximov II, Alnæs D, Westlye LT. Towards an optimised processing pipeline for 631 diffusion magnetic resonance imaging data: Effects of artefact corrections on diffusion metrics 632 and their age associations in UK Biobank. Human brain mapping. 2019;40(14):4146-62.

- 633 61. Chen G, Cox RW, Glen DR, Rajendra JK, Reynolds RC, Taylor PA. A tail of two sides: 634 Artificially doubled false positive rates in neuroimaging due to the sidedness choice with t-tests. 635 Human brain mapping. 2019;40(3):1037-43.
- 636 62. Mueller SC, Landré L, Wierckx K, T'Sjoen G. A Structural Magnetic Resonance Imaging 637 Study in Transgender Persons on Cross-Sex Hormone Therapy. Neuroendocrinology. 638 2017;105(2):123-30.
- 639 63. Simon L, Kozák LR, Simon V, Czobor P, Unoka Z, Szabó Á, et al. Regional grey matter
 640 structure differences between transsexuals and healthy controls--a voxel based morphometry
 641 study. PLoS One. 2013;8(12):e83947.
- 642 64. Hoekzema E, Schagen SE, Kreukels BP, Veltman DJ, Cohen-Kettenis PT, Delemarre-643 van de Waal H, et al. Regional volumes and spatial volumetric distribution of gray matter in the 644 gender dysphoric brain. Psychoneuroendocrinology. 2015;55:59-71.
- 645 65. Luders E, Sánchez FJ, Gaser C, Toga AW, Narr KL, Hamilton LS, et al. Regional gray 646 matter variation in male-to-female transsexualism. Neuroimage. 2009;46(4):904-7.
- 647 66. Zubiaurre-Elorza L, Junque C, Gómez-Gil E, Segovia S, Carrillo B, Rametti G, et al. 648 Cortical thickness in untreated transsexuals. Cerebral cortex (New York, NY : 1991). 649 2013;23(12):2855-62.
- 650 67. Feusner JD, Lidström A, Moody TD, Dhejne C, Bookheimer SY, Savic I. Intrinsic 651 network connectivity and own body perception in gender dysphoria. Brain imaging and 652 behavior. 2017;11(4):964-76.
- 653 68. Guillamon Á, Junque C, Gómez-Gil E. A Review of the Status of Brain Structure 654 Research in Transsexualism. Archives of Sexual Behavior. 2016;45(7):1615-48.
- 655 69. O'Connor DB, Archer J, Hair WM, Wu FC. Activational effects of testosterone on 656 cognitive function in men. Neuropsychologia. 2001;39(13):1385-94.
- 657 70. Aleman A, Bronk E, Kessels RPC, Koppeschaar HPF, van Honk J. A single 658 administration of testosterone improves visuospatial ability in young women. 659 Psychoneuroendocrinology. 2004;29(5):612-7.
- 71. Peters SK, Dunlop K, Downar J. Cortico-Striatal-Thalamic Loop Circuits of the Salience
 Network: A Central Pathway in Psychiatric Disease and Treatment. Frontiers in Systems
 Neuroscience. 2016;10.
- 663 72. Harrington GS, Farias ST. Sex differences in language processing: functional MRI
 664 methodological considerations. Journal of magnetic resonance imaging : JMRI.
 665 2008;27(6):1221-8.
- 666 73. Duerden EG, Arsalidou M, Lee M, Taylor MJ. Lateralization of affective processing in 667 the insula. Neuroimage. 2013;78:159-75.
- 668 74. Klabunde M, Weems CF, Raman M, Carrion VG. The moderating effects of sex on 669 insula subdivision structure in youth with posttraumatic stress symptoms. Depression and 670 anxiety. 2017;34(1):51-8.
- 671 75. Eisenberger NI, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. An fMRI study of
 672 cytokine-induced depressed mood and social pain: the role of sex differences. Neuroimage.
 673 2009;47(3):881-90.
- 674 76. Spurny-Dworak B, Handschuh P, Spies M, Kaufmann U, Seiger R, Klöbl M, et al.
- 675 Effects of sex hormones on brain GABA and glutamate levels in a cis- and transgender cohort.
- 676 Psychoneuroendocrinology. 2022;138:105683.

677 77. Lin CS, Ku HL, Chao HT, Tu PC, Li CT, Cheng CM, et al. Neural network of body 678 representation differs between transsexuals and cissexuals. PLoS One. 2014;9(1):e85914.

679 78. Savli M, Bauer A, Mitterhauser M, Ding Y-S, Hahn A, Kroll T, et al. Normative database
680 of the serotonergic system in healthy subjects using multi-tracer PET. Neuroimage.
681 2012;63(1):447-59.

682 79. Holmberg M, Arver S, Dhejne C. Supporting sexuality and improving sexual function in 683 transgender persons. Nature reviews Urology. 2019;16(2):121-39.

684 80. Van Dijk KR, Hedden T, Venkataraman A, Evans KC, Lazar SW, Buckner RL. Intrinsic 685 functional connectivity as a tool for human connectomics: theory, properties, and optimization. 686 Journal of neurophysiology. 2010;103(1):297-321.

81. Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher A, Toye K, et al. Crosssex hormone therapy in trans persons is safe and effective at short-time follow-up: results from
the European network for the investigation of gender incongruence. The journal of sexual
medicine. 2014;11(8):1999-2011.

691 82. Wierckx K, Elaut E, Van Caenegem E, Van De Peer F, Dedecker D, Van Houdenhove 692 E, et al. Sexual desire in female-to-male transsexual persons: exploration of the role of 693 testosterone administration. European Journal of Endocrinology. 2011;165(2):331-7.

83. van Dijk D, Dekker M, Conemans EB, Wiepjes CM, de Goeij EGM, Overbeek KA, et al.
Explorative Prospective Evaluation of Short-Term Subjective Effects of Hormonal Treatment
in Trans People-Results from the European Network for the Investigation of Gender
Incongruence. J Sex Med. 2019;16(8):1297-309.

84. Davis SR, Braunstein GD. Efficacy and Safety of Testosterone in the Management of
Hypoactive Sexual Desire Disorder in Postmenopausal Women. The Journal of Sexual
Medicine. 2012;9(4):1134-48.

701 85. van Anders SM. Testosterone and Sexual Desire in Healthy Women and Men. Archives
702 of Sexual Behavior. 2012;41(6):1471-84.

70386.Uddin LQ, Kinnison J, Pessoa L, Anderson ML. Beyond the tripartite cognition-emotion-704interoception model of the human insular cortex. J Cogn Neurosci. 2014;26(1):16-27.

87. Bittoni C, Kiesner J. When the brain turns on with sexual desire: fMRI findings, issues,
and future directions. Sexual Medicine Reviews. 2023;11(4):296-311.

88. Cacioppo S, Bianchi-Demicheli F, Frum C, Pfaus JG, Lewis JW. The Common Neural
Bases Between Sexual Desire and Love: A Multilevel Kernel Density fMRI Analysis. The
Journal of Sexual Medicine. 2012;9(4):1048-54.

89. Cera N, Castelhano J, Oliveira C, Carvalho J, Quinta Gomes AL, Peixoto MM, et al.
The role of anterior and posterior insula in male genital response and in visual attention: an
exploratory multimodal fMRI study. Scientific Reports. 2020;10(1):18463.

713 90. Oei NY, Rombouts SA, Soeter RP, van Gerven JM, Both S. Dopamine modulates 714 reward system activity during subconscious processing of sexual stimuli. 715 Neuropsychopharmacology. 2012;37(7):1729-37.

716 91. Calabrò RS, Cacciola A, Bruschetta D, Milardi D, Quattrini F, Sciarrone F, et al. 717 Neuroanatomy and function of human sexual behavior: A neglected or unknown issue? Brain

- 718 Behav. 2019;9(12):e01389.
- 719



721

722 Figure 1: Structural changes after gender-affirming hormone therapy. (a) Shows the 723 significant changes derived from the voxel based morphometry (VBM) analysis, whereas (b) 724 shows the mean diffusivity changes in gray matter for all transgender and cisgender groups 725 after a median of 4.5 months of gender-affirming hormone therapy. (c) Indicates the 726 overlapping regions between the VBM and DWI analyses.



728 Figure 2: Voxel based morphometry regional changes. Each bar represents the change in 729 gray matter density (GMD) after 4 months of gender-affirming hormone therapy (GHT), where 730 the hatched bars represent the cisgender groups of male (CM) and female controls (CW) and 731 the solid bars the transgender groups, transmale (TM) and transfemale (TW). Here widespread 732 regional interactions can be found in the TW group when compared to both CM and CW. 733 whereas TM showed less regional interactions, however the significant interactions showed a 734 greater magnitude of change. An increase in GMD was found TM, whereas a decrease was found in TW after a median of 4.5 months of GHT when compared to both CM and CW. 735 736 Significant group-by-time interactions are denoted with a *.



Figure 3: Mean diffusivity regional changes. Each bar represents the average diffusivity change reflective of microstructural alterations after 4 months of gender-affirming hormone therapy, where the hatched bars represent the cisgender groups of male (CM) and female controls (CW) and the solid bars the transgender groups, transmale (TM) and transfemale (TW). Here, changes a decrease in both TM vs CW or CM and also TW vs CM were found. Significant group-by-time interactions are denoted with a *.

	cisgender women		cisgender men		transgender women		transgender men	
N(VBM + DWI)		20		11		20		10
Age [years]	25.3 ± 6.7		26.5 ± 8.0		28.6 ± 9.3		24.75 ± 7.3	
Completed	M1	M2	M1	M2	M1	M2	M1	M2
N(PET)	9	3	8	3	7	5	11	6
	Pre	Post	Pre	Post	Pre	Post	Pre	Post
DHEAS (µg/ml)	3.2 ± 0.9	3.2 ± 1.0	3.8 ± 1.9	2.6 ± 1.3	3.9 ± 1.1	3.8 ± 1.3	3.2 ± 1.9	3.3 ± 1.9
Estradiol (pg/ml)	81.2 ± 56.7	112.1 ± 79.5	22.7 ± 10.3	22.9 ± 9.0	35.7 ± 16.6	290.0 ± 299.1	111.2 ± 74.9	59.3 ± 50.3
FSH (µU/ml)	4.9 ± 1.4	4.9 ± 2.8	3.8 ± 1.6	3.8 ± 1.5	3.3 ± 1.7	0.2 ± 0.1	4.5 ± 2.5	5.6 ± 3.6
LH (μU/ml)	9.8 ± 6.4	9.5 ± 6.9	5.8 ± 1.9	6.5 ± 2.3	6.5 ± 2.9	0.1 ± 0.1	9.6 ± 5.9	8.6 ± 8.8
Progesterone (ng/ml)	1.3 ± 1.3	4.9 ± 5.6	0.4 ± 0.3	0.3 ± 0.2	0.3 ±0.2	0.8 ± 0.9	4.9 ± 6.4	0.3 ± 0.2
SHBG (nmol/L)	67.4 ± 28.5	69.6 ± 27.6	45.3 ± 25.0	43.2 ± 19.3	45.7 ± 21.5	70.2 ± 39.4	65.3 ± 36.3	36.3 ± 15.1
Testosterone (ng/ml)	0.4 ± 0.2	0.3 ± 0.1	5.6 ± 2.1	5.0 ± 1.2	5.7 ± 1.7	0.3 ± 0.2	0.4 ± 0.2	4.3 ± 2.1

Table 1: Demographics of all participants for both DWI + VBM and PET analyses, each 750

751 divided into their respective subgroups. Age is given from the inclusion date. Hormone levels

752 for the pre-treatment assessment and cisgender participants are provided for comparison only

753 and were not used as covariates in the statistical analyses.